224 related articles for article (PubMed ID: 28828489)
1. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Siegel M; Manabe YC; Frank I; Ho K; Santana J; Stekler JD; Swaminathan S; McCauley M; Hodder S; Mayer KH
Ann Intern Med; 2017 Sep; 167(6):384-393. PubMed ID: 28828489
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu A; Frank I; Ho K; Santana J; Stekler JD; McCauley M; Mayer KH
J Infect Dis; 2017 Jan; 215(2):238-246. PubMed ID: 27811319
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
McGowan I; Wilkin T; Landovitz RJ; Wu C; Chen Y; Marzinke MA; Hendrix CW; Richardson P; Eshleman SH; Andrade A; Chege W; Anderson PL; McCauley M; Farley J; Mayer KH; Anton P; Brand RM; Cranston RD; Gulick R
AIDS; 2019 Feb; 33(2):237-246. PubMed ID: 30557160
[TBL] [Abstract][Full Text] [Related]
7. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
[TBL] [Abstract][Full Text] [Related]
8. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
10. Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Chan ES; Landay AL; Brown TT; Ribaudo HJ; Mirmonsef P; Ofotokun I; Weitzmann MN; Martinson J; Klingman KL; Eron JJ; Fichtenbaum CJ; Plants J; Taiwo BO
AIDS; 2016 Aug; 30(13):2091-7. PubMed ID: 27281061
[TBL] [Abstract][Full Text] [Related]
11. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.
Kapadia SN; Wu C; Mayer KH; Wilkin TJ; Amico KR; Landovitz RJ; Andrade A; Chen YQ; Chege W; McCauley M; Gulick RM; Schackman BR
PLoS One; 2018; 13(12):e0206577. PubMed ID: 30586364
[TBL] [Abstract][Full Text] [Related]
12. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S; Hughes JP; Bock P; Ouma SG; Hunidzarira P; Kalonji D; Kayange N; Makhema J; Mandima P; Mathew C; Spooner E; Mpendo J; Mukwekwerere P; Mgodi N; Ntege PN; Nair G; Nakabiito C; Nuwagaba-Biribonwoha H; Panchia R; Singh N; Siziba B; Farrior J; Rose S; Anderson PL; Eshleman SH; Marzinke MA; Hendrix CW; Beigel-Orme S; Hosek S; Tolley E; Sista N; Adeyeye A; Rooney JF; Rinehart A; Spreen WR; Smith K; Hanscom B; Cohen MS; Hosseinipour MC;
Lancet; 2022 May; 399(10337):1779-1789. PubMed ID: 35378077
[TBL] [Abstract][Full Text] [Related]
13. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
14. Neurocognition with maraviroc compared with tenofovir in HIV.
Robertson KR; Miyahara S; Lee A; Brown TT; Chan ES; Berzins B; Rusin D; Eron JJ; Taiwo BO;
AIDS; 2016 Sep; 30(15):2315-21. PubMed ID: 27333088
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Milinkovic A; Benn P; Arenas-Pinto A; Brima N; Copas A; Clarke A; Fisher M; Schembri G; Hawkins D; Williams A; Gilson R;
J Antimicrob Chemother; 2017 Jun; 72(6):1760-1768. PubMed ID: 28369381
[TBL] [Abstract][Full Text] [Related]
16. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
[TBL] [Abstract][Full Text] [Related]
17. Preexposure prophylaxis for HIV infection among African women.
Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D;
N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
[TBL] [Abstract][Full Text] [Related]
19. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
